Company profile
PHARVARIS N.V.
NASDAQ:PHVSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DEUCRICTIBANT | phase3 | — | 6 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04618211 | phase2 | completed | 2021-02-03 | 2022-09-23 | Pharvaris Netherlands B.V. | Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema |
| NCT05047185 | phase2 | terminated | 2022-04-19 | 2025-06-30 | Pharvaris Netherlands B.V. | Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II |
| NCT05396105 | phase2_3 | enrolling_by_invitation | 2022-12-28 | 2027-06-01 | Pharvaris Netherlands B.V. | Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema |
| NCT06679881 | phase3 | enrolling_by_invitation | 2025-02-01 | 2028-12-01 | Pharvaris Netherlands B.V. | Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE |
| NCT06669754 | phase3 | active_not_recruiting | 2024-12-01 | 2026-08-01 | Pharvaris Netherlands B.V. | Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE |
FDA applications (0)
No records yet.